DK3041842T3 - Spirocycliske forbindelser som tryptophan-hydroxylase-inhibitorer - Google Patents

Spirocycliske forbindelser som tryptophan-hydroxylase-inhibitorer Download PDF

Info

Publication number
DK3041842T3
DK3041842T3 DK14786383.1T DK14786383T DK3041842T3 DK 3041842 T3 DK3041842 T3 DK 3041842T3 DK 14786383 T DK14786383 T DK 14786383T DK 3041842 T3 DK3041842 T3 DK 3041842T3
Authority
DK
Denmark
Prior art keywords
hydroxylase inhibitors
tryptophan hydroxylase
spirocyclic compounds
spirocyclic
compounds
Prior art date
Application number
DK14786383.1T
Other languages
English (en)
Inventor
Lombaert Stéphane De
Daniel R Goldberg
Kenneth Brameld
Eric Brian Sjogren
Andrew Scribner
Original Assignee
Roivant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roivant Sciences Gmbh filed Critical Roivant Sciences Gmbh
Application granted granted Critical
Publication of DK3041842T3 publication Critical patent/DK3041842T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK14786383.1T 2013-09-06 2014-09-05 Spirocycliske forbindelser som tryptophan-hydroxylase-inhibitorer DK3041842T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361874545P 2013-09-06 2013-09-06
US201361899943P 2013-11-05 2013-11-05
US201462004385P 2014-05-29 2014-05-29
PCT/US2014/054202 WO2015035113A1 (en) 2013-09-06 2014-09-05 Spirocyclic compounds as tryptophan hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
DK3041842T3 true DK3041842T3 (da) 2020-01-20

Family

ID=51743540

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14786383.1T DK3041842T3 (da) 2013-09-06 2014-09-05 Spirocycliske forbindelser som tryptophan-hydroxylase-inhibitorer

Country Status (31)

Country Link
US (8) US9199994B2 (da)
EP (1) EP3041842B8 (da)
JP (1) JP6470290B2 (da)
KR (1) KR102336075B1 (da)
CN (1) CN105764902B (da)
AR (1) AR097571A1 (da)
AU (1) AU2014315109B2 (da)
CA (1) CA2922933C (da)
CL (1) CL2016000509A1 (da)
CY (1) CY1122652T1 (da)
DK (1) DK3041842T3 (da)
EA (1) EA032304B1 (da)
EC (1) ECSP16014324A (da)
ES (1) ES2780828T3 (da)
HK (1) HK1225720A1 (da)
HR (1) HRP20200098T1 (da)
HU (1) HUE047574T2 (da)
IL (1) IL244315B (da)
LT (1) LT3041842T (da)
MX (1) MX371191B (da)
MY (1) MY186265A (da)
PE (1) PE20160648A1 (da)
PH (1) PH12016500416B1 (da)
PL (1) PL3041842T3 (da)
PT (1) PT3041842T (da)
RS (1) RS59871B1 (da)
SG (2) SG10202013041QA (da)
SI (1) SI3041842T1 (da)
TW (1) TWI652267B (da)
UA (1) UA119247C2 (da)
WO (1) WO2015035113A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN107176940B (zh) * 2016-03-09 2019-05-28 江苏正大丰海制药有限公司 一种替卡法林的制备方法
WO2018060949A1 (en) 2016-09-30 2018-04-05 Roivant Sciences Gmbh Tryptophan hydroxylase inhibitors for use in the treatment of liver diseases
AR110150A1 (es) 2016-11-09 2019-02-27 Roivant Sciences Gmbh Procesos para la preparación de inhibidores de tph1
US10472313B1 (en) 2018-02-18 2019-11-12 Graphene 3D Lab Inc. Process for synthesizing trifluoroketones
MX2021005559A (es) * 2018-11-14 2021-09-10 Altavant Sciences Gmbh Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización.
KR20210105343A (ko) * 2018-11-16 2021-08-26 알타반트 사이언시스 게엠베하 폐동맥 고혈압 및 관련 폐동맥 고혈압의 치료 방법
US20200188398A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating sarcoidosis-associated pulmonary hypertension
US20200188399A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
AU2020213746A1 (en) 2019-01-30 2021-08-19 Altavant Sciences Gmbh A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl
MX2021011224A (es) * 2019-03-15 2021-12-10 Altavant Sciences Gmbh Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria.
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
US20230074252A1 (en) 2020-01-31 2023-03-09 Altavant Sciences Gmbh Dosages and methods for treating pulmonary arterial hypertension with rodatristat
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700613A (ko) 1989-05-16 1992-08-10 지구르트 퓌터 약제제
DE69730033T2 (de) 1996-08-28 2005-07-21 The Procter & Gamble Company, Cincinnati Spirocyclisch metalloprotease inhibitoren
DK1263745T3 (da) 2000-03-07 2004-08-16 Aventis Pharma Gmbh Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiaxol-2-oner og anvendelse deraf til inhibering af hormonfölsom lipase
US7067517B2 (en) 2001-12-14 2006-06-27 Nero Nordisk A/S Use of compounds for decreasing activity of hormone-sensitive lipase
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
KR20060017791A (ko) 2003-06-12 2006-02-27 노보 노르디스크 에이/에스 호르몬-민감성 리파제 억제제로서의 피리디닐 카르바메이트
JP2006527212A (ja) 2003-06-12 2006-11-30 ノボ ノルディスク アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102005002130A1 (de) 2005-01-17 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte N-Aminomethylensulfonamide, ihre Herstellung und Verwendung als Arzneimittel
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
PT1984344E (pt) 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
US8252803B2 (en) * 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
JP5248600B2 (ja) 2007-05-16 2013-07-31 イーライ リリー アンド カンパニー トリアゾリルアミノピリミジン化合物
KR20100046189A (ko) 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
BRPI0813835A2 (pt) 2007-07-26 2017-06-06 Lexicon Pharmaceuticals Inc métodos de afetar o trânsito gastrointestinal e esvaziamento gástrico, e compostos úteis a esse respeito
US20100255001A1 (en) 2007-09-24 2010-10-07 Universität Zürich Prorektorat Mnw Blockers of serotonin and its receptors for the treatment of hepatitis
NZ588737A (en) 2008-03-31 2012-05-25 Univ Columbia Methods of diagnosing, preventing and treating bone mass diseases
CN101591332B (zh) 2008-05-30 2014-04-16 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
CN104045626B (zh) 2008-05-30 2017-01-11 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
TW201022267A (en) 2008-10-23 2010-06-16 Gruenenthal Gmbh Substituierte pyrimidin-und triazin-derivate
WO2010056992A1 (en) 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
WO2010065333A1 (en) 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
WO2010109442A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of desloratadine
WO2010147094A1 (ja) 2009-06-16 2010-12-23 小野薬品工業株式会社 スピロ結合した環状基を有する化合物およびその用途
US8796297B2 (en) * 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
WO2011053977A1 (en) 2009-11-02 2011-05-05 The Trustees Of Columbia University In The City Of New York Compounds and methods for inhibiting serotonin synthesis
US20120316171A1 (en) 2009-11-05 2012-12-13 Tamas Oravecz Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer
WO2011063181A1 (en) 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
WO2011100285A1 (en) 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
JP2013519732A (ja) * 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
EP2624698A4 (en) * 2010-10-08 2014-10-08 Abbvie Inc Furo [3,2-D] PYRIMIDINE COMPOUNDS
TW201245183A (en) 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
AU2012326383B2 (en) 2011-10-17 2017-07-27 Tersera Therapeutics Llc Solid dosage forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
US9717727B2 (en) 2011-11-17 2017-08-01 The Trustees Of Columbia University In The City Of New York Methods of treating and preventing leukemia and other cancers of the blood and bone
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802584B1 (en) 2012-01-13 2015-11-18 Novartis AG Salts of an ip receptor agonist
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
WO2014082034A1 (en) 2012-11-26 2014-05-30 Lexicon Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome
CA2900413A1 (en) 2013-02-15 2014-08-21 Mcmaster University A method of treating obesity
WO2014195847A2 (en) 2013-06-03 2014-12-11 Actelion Pharmaceuticals Ltd Novel use of stable isotope labeled l-tryptophan
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
JP6561055B2 (ja) 2013-11-19 2019-08-14 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 三環式イミダゾール化合物
AR098436A1 (es) 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
EP3061761A1 (en) 2015-02-24 2016-08-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
WO2016177690A1 (en) 2015-05-04 2016-11-10 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds

Also Published As

Publication number Publication date
US20180256574A1 (en) 2018-09-13
US20190282575A1 (en) 2019-09-19
TW201536785A (zh) 2015-10-01
MX371191B (es) 2020-01-22
PE20160648A1 (es) 2016-07-09
CY1122652T1 (el) 2021-05-05
ES2780828T3 (es) 2020-08-27
CN105764902B (zh) 2019-02-15
HK1225720A1 (zh) 2017-09-15
AU2014315109B2 (en) 2018-08-09
PH12016500416A1 (en) 2016-05-16
HRP20200098T1 (hr) 2020-04-03
AR097571A1 (es) 2016-03-23
EP3041842B1 (en) 2019-10-23
IL244315B (en) 2018-11-29
EA201690534A1 (ru) 2016-08-31
PL3041842T3 (pl) 2020-05-18
US20170095476A1 (en) 2017-04-06
CL2016000509A1 (es) 2016-08-19
US10045988B2 (en) 2018-08-14
US9199994B2 (en) 2015-12-01
BR112016004909A8 (pt) 2020-02-11
US9750740B2 (en) 2017-09-05
ECSP16014324A (es) 2017-10-31
CN105764902A (zh) 2016-07-13
US10350208B2 (en) 2019-07-16
US20160096836A1 (en) 2016-04-07
EP3041842A1 (en) 2016-07-13
US10946018B2 (en) 2021-03-16
US20210205305A1 (en) 2021-07-08
UA119247C2 (uk) 2019-05-27
TWI652267B (zh) 2019-03-01
SG10201802118QA (en) 2018-04-27
US10660893B2 (en) 2020-05-26
AU2014315109A1 (en) 2016-03-17
SI3041842T1 (sl) 2020-03-31
MX2016002936A (es) 2016-10-07
NZ717556A (en) 2021-04-30
HUE047574T2 (hu) 2020-05-28
US11759462B2 (en) 2023-09-19
IL244315A0 (en) 2016-04-21
PH12016500416B1 (en) 2016-05-16
RS59871B1 (sr) 2020-03-31
MY186265A (en) 2021-06-30
JP6470290B2 (ja) 2019-02-13
SG10202013041QA (en) 2021-02-25
US9512122B2 (en) 2016-12-06
US20150080393A1 (en) 2015-03-19
US20180092918A1 (en) 2018-04-05
PT3041842T (pt) 2020-02-21
CA2922933C (en) 2021-08-03
US20200237760A1 (en) 2020-07-30
LT3041842T (lt) 2020-02-10
KR102336075B1 (ko) 2021-12-08
CA2922933A1 (en) 2015-03-12
EP3041842B8 (en) 2019-12-04
JP2016530299A (ja) 2016-09-29
WO2015035113A1 (en) 2015-03-12
KR20160055190A (ko) 2016-05-17
EA032304B1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
DK3041842T3 (da) Spirocycliske forbindelser som tryptophan-hydroxylase-inhibitorer
DK3786162T3 (da) Bipyrazolderivater som jak-inhibitorer
DK3071203T3 (da) Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
DK3604511T3 (da) Cas-varianter til genredigering
DK3181567T3 (da) Pyrazolopyrimidinforbindelser som kinasehæmmere
DK3087071T3 (da) Tricykliske forbindelser som anticancermidler
DK2981526T3 (da) Naphthylureaderivater til anvendelse som kinaseinhibitorer
DK3019496T3 (da) Pyrimidinderivater som kinaseinhibitorer
DK2978759T3 (da) Benzimidazolonderivater som bromdomæneinhibitorer
DK3342771T3 (da) Heterocykliske amider som kinaseinhibitorer
EP3038618A4 (en) Substituted indole mcl-1 inhibitors
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
DK3495367T3 (da) Substituerede tricykliske forbindelser som fgfr-inhibitorer
DK3060041T3 (da) Prostacyclinforbindelser
DK3313838T3 (da) Polycykliske amidderivater som cdk9-inhibitorer
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
DK3083617T3 (da) Isochromene derivater som phosphoinositid 3-kinase-inhibitorer
HK1223090A1 (zh) -氮雜吲哚衍生物
DK2970089T3 (da) Substituerede aromatiske forbindelser
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
DK2952513T3 (da) Azolbenzenderivat
DK3007725T3 (da) Beta-glycolipider til anvendelse som adjuvanser
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
HK1226072A1 (zh) 作為bcl-3抑制劑的2-苯甲酰氨基苯甲酰胺衍生物
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti